Evidence map›Paper›PMID 31932992›Full record

ReviewCurrent cardiology reports2020

Harnessing Cardiac Regeneration as a Potential Therapeutic Strategy for AL Cardiac Amyloidosis.

Shaurya Joshi, Alessandro Evangelisti, Ronglih Liao, Kevin M Alexander

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Shaurya JoshiDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Alessandro EvangelistiStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Ronglih LiaoStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Kevin M AlexanderStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. kevalex@stanford.edu.
Cardiovascular Institute of the South · USHarvard University · USStanford University · US

Funding

Mulan: a novel regulator of mitochondrial dynamics, mitophagy and heart functionR01HL132511 · NHLBI · STANFORD UNIVERSITY · PI LIAO, RONGLIH, ZERVOS, ANTONIS S · 2017 to 2020
$2.8M
Metabolic underpinnings of AL amyloid cardiomyopathyR01HL128135 · NHLBI · STANFORD UNIVERSITY · PI LIAO, RONGLIH · 2015 to 2018
$2.5M
NHLBI NIH HHS R01 HL128135NHLBI NIH HHS R01 HL132511
6 · The paper itself

Abstract

purpose of reviewCardiac regeneration has received much attention as a possible means to treat various forms of cardiac injury. This review will explore the field of cardiac regeneration by highlighting the existing animal models, describing the involved molecular pathways, and discussing attempts to harness cardiac regeneration to treat cardiomyopathies. RECENT

findingsLight chain cardiac amyloidosis is a degenerative disease characterized by progressive heart failure due to amyloid fibril deposition and light chain-mediated cardiotoxicity. Recent findings in a zebrafish model of light chain amyloidosis suggest that cardiac regenerative confers a protective effect against this disease. Cardiac regeneration remains an intriguing potential tool for treating cardiovascular disease. Degenerative diseases, such as light chain cardiac amyloidosis, may be particularly suited for therapeutic interventions that target cardiac regeneration. Further studies are needed to translate preclinical findings for cardiac regeneration into effective therapies.

Indexed as

RegenerationAmyloidosisAnimalsCardiomyopathiesCardiotoxicityHeart FailureHumansImmunoglobulin Light ChainsMyocardiumZebrafishImmunoglobulin Light ChainsAmyloidosisCardiac regenerationCardiomyopathyLight chainZebrafish

Identifiers

PMID31932992
OpenAlexW2999809738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.